A PT-141 nasal spray is something only a compounding pharmacy makes, because the one approved bremelanotide product, Vyleesi, is an injection given with a single-dose autoinjector[1]. So when you price a spray, you are pricing a compounded formulation with no approved version to compare it against.
PT-141 is the research name for bremelanotide, and the injection and the spray contain the same peptide in different delivery forms. What the spray costs, and what is known about it, is below.
What the spray costs against the injection
$187
Typical compounded nasal spray month (8 sellers)
$199
Typical compounded injection month (28 sellers)
$99
Vyleesi, 4-dose box, cash
Source: vyleesi.com
The nasal market runs from $151 to $249 a month across 8 sellers, a small market where one seller’s change can move the typical figure. Seller prices were read through September 2026.
Vyleesi is sold differently: the maker’s cash price covers a box of 4 doses for patients whose commercial insurance does not cover it[2], and patients on government-funded programs are not eligible for the maker’s assistance[2]. The brand’s full cost and coverage picture is in Vyleesi cost, and the compounded injection market is in PT-141 cost.
What the approved product’s label says
Vyleesi is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder, and its label says it is not indicated for postmenopausal women or for men[1]. The label dose is 1.75 mg injected under the skin at least 45 minutes before anticipated sexual activity[1].
The label also sets limits that shape a monthly bill: no more than one dose within 24 hours, and more than 8 doses a month is not recommended[1]. A spray bought by the month should be read against those numbers, because the approved label does not support daily use.
What the nasal trial used
The nasal route has thin human data. A 2006 trial gave 18 premenopausal women with sexual arousal disorder a single 20 mg intranasal dose or placebo, in a crossover design[3]. More women reported moderate or high desire after bremelanotide than after placebo, but vaginal blood flow while watching erotic video did not change significantly[3].
The trials behind the approved product used the injection. A dose-finding trial had women self-inject 0.75, 1.25 or 1.75 mg as desired over 12 weeks, with efficacy data on 327 patients[4]. No label sets a nasal dose, and none of these studies establishes one for home use.
Questions to ask the seller
Because the spray has no approved counterpart, the questions are about the pharmacy and the product itself. Ask which pharmacy compounds it, how much bremelanotide each spray delivers, and how many sprays the monthly price covers. How prescribing works for this compound is in PT-141 prescription, and each seller’s injection price is on the PT-141 price board.